US stocks up on COVID-19 antibody drugs amid shortage concerns

Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.

By Ned Pagliarulo • Sept. 15, 2021

CureVac scales back mRNA manufacturing for coronavirus vaccine

The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand. 

By Shoshana Dubnow • Updated Sept. 15, 2021

Moderna expands mRNA vaccine supply in deal with new biotech producer

The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.

By Shoshana Dubnow • Sept. 8, 2021

Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant

While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.

By Jonathan Gardner • Aug. 10, 2021

Amgen, expecting higher demand for its medicines, to build plant in North Carolina

The biotech is also constructing a new factory in Ohio and, between the two, expects to investment nearly $1 billion over the next few years.

By Kristin Jensen • Aug. 4, 2021

A pharma merger's impact ripples across West Virginia as Viatris plant closes

One of the country's oldest and largest drug manufacturing plants shut down Saturday, a consequence of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.

By Shoshana Dubnow • July 30, 2021

Bluebird preps for split by selling manufacturing plant to well-funded startup

The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

By Kristin Jensen • July 29, 2021

BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent. 

By Jonathan Gardner • July 26, 2021

Trends shaping biopharma's role in the healthcare ecosystem

Four trends are shaping the healthcare ecosystem. These present new opportunities for biopharma.

By Pratap Khedkar and Jude Konzelmann • July 26, 2021

Unique commercial experience primes Avid Bioservices for growth

Discover the bioservices and manufacturing efforts that have made an impact within the biological manufacturing field.

By Nick Green, Chief Executive Officer, Avid Bioservices • June 28, 2021

Lyophilized products are on the rise: Here's what you need to know

To extend the shelf life and improve stability of biopharmaceuticals, a freeze-drying process—and a partner—can help.

By Kate Silver • June 14, 2021

UK drug contractor to be sold to private equity firm in $1.4B deal

Through a subsidiary, The Carlyle Group will pay a 27% premium to acquire Vectura, a CDMO that specializes in inhaled medicines.

By Kristin Jensen • May 26, 2021

Emergent CEO defends company from criticism of error that ruined vaccine doses

The company expects to respond within days to a long list of findings FDA officials made in an inspection of Emergent's Baltimore plant earlier this month.

By Ned Pagliarulo • April 30, 2021

Moderna plans to triple coronavirus vaccine production next year

The biotech aims to double capacity at plants in Switzerland and Spain, and by 50% at U.S. sites. The total number, however, will depend on the mix of primary and booster doses.

By Jonathan Gardner • April 29, 2021

Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens

Gilead will donate at least 450,000 vials of Veklury, while Merck licensed its experimental antiviral molnupiravir to five generic drugmakers in India. 

By Ned Pagliarulo • April 27, 2021

Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine

The French pharma has agreed to "fill and finish" up to 200 million vials of Moderna's shot at its New Jersey plant, the third such manufacturing deal it struck with other vaccine developers. 

By Ned Pagliarulo • April 26, 2021

FDA cites Emergent for failings at plant that contaminated J&J doses

A recent nine-day inspection by agency officials found numerous breaches of manufacturing standards and inadequate training for factory employees. 

By Ned Pagliarulo • April 22, 2021

J&J to oversee vaccine production at Emergent factory that ruined doses

The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.

By Ned Pagliarulo • April 5, 2021

Manufacturing mix-up could blunt supply boost from J&J vaccine

One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses. 

By Ned Pagliarulo • April 1, 2021

How to navigate Health Canada XML PM requirements

Learn the latest about XML PM mandates and timelines from structured labeling experts.

March 22, 2021

Paving the way towards the biomanufacturing facility of the future

Technologies that enable bioprocessing 4.0 are creating the roadmap to the facility of the future.

By Merrilee Whitney, Head of the BioContinuum™ platform • March 15, 2021

Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots

The U.S. is now averaging more than 2 million doses given each day, a pace that will help President Joe Biden meet his target of 100 million shots in 100 days well ahead of schedule. 

By Ned Pagliarulo • March 11, 2021

Merck to help J&J make vaccine doses in White House-brokered deal

The U.S. government will give Merck $269 million to help the drugmaker retool two of its facilities to make J&J's one-dose shot. 

By Jonathan Gardner • Updated March 2, 2021

Moderna, Pfizer ready multi-pronged plans for coronavirus variants

Moderna has delivered a modified version of its vaccine to NIH scientists, while Pfizer has begun testing of an additional booster shot in a clinical trial, both precautionary steps against emerging strains.

By Jonathan Gardner , Ben Fidler • Updated Feb. 25, 2021

Pfizer set to double weekly production of coronavirus vaccine

The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday.

By Ned Pagliarulo • Feb. 19, 2021